Antineoplastics
1
Reactions 423 - 17 Oct 1992 Antineoplastics Melanocytic naevi in children: incidence study The number of melanocytic naevi ≥ 2mm significantly increased compared with baseline and with age-matched controls in 22 children 1 year after completing a 2-year maintenance chemotherapy programme for the treatment of haematological malignancies. The children were aged 1-14 years at diagnosis of their leukaemia or Hodgkin’s disease. For the majority of patients, induction therapy included vincristine, prednisolone, daunorubicin, asparaginase and intrathecal methotrexate. Maintenance therapy consisted of monthly courses of vincristine and prednisolone, weekly methotrexate and daily mercaptopurine. In the original 29 patients enrolled in the study, the number of naevi ≥ 2mm ranged from 0-34 (median 4) per child at the beginning of maintenance antineoplastic therapy. Three years later, the number of naevi in the 22 evaluable children ranged from 30-199 (median 76) per child, with the mean increase in melanocytic naevi being 66 per child. Author comment: ‘Though we know that children treated in childhood for malignancies with chemotherapy are at risk of developing second malignancies, malignant melanoma is not at present recognised as such a second malignancy. Long term follow up of these children already occurs, and it is recommended that they should have periodic skin examinations.’ Baird EA, et al. Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi. BMJ 305: 799-801, 3 Oct 1992 - Scotland 800155415 1 Reactions 17 Oct 1992 No. 423 0114-9954/10/0423-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 423 - 17 Oct 1992
Antineoplastics
Melanocytic naevi in children: incidence studyThe number of melanocytic naevi ≥ 2mm significantly
increased compared with baseline and with age-matchedcontrols in 22 children 1 year after completing a 2-yearmaintenance chemotherapy programme for the treatment ofhaematological malignancies. The children were aged 1-14years at diagnosis of their leukaemia or Hodgkin’s disease.
For the majority of patients, induction therapy includedvincristine, prednisolone, daunorubicin, asparaginase andintrathecal methotrexate. Maintenance therapy consisted ofmonthly courses of vincristine and prednisolone, weeklymethotrexate and daily mercaptopurine.
In the original 29 patients enrolled in the study, the numberof naevi ≥ 2mm ranged from 0-34 (median 4) per child at thebeginning of maintenance antineoplastic therapy. Three yearslater, the number of naevi in the 22 evaluable children rangedfrom 30-199 (median 76) per child, with the mean increase inmelanocytic naevi being 66 per child.
Author comment: ‘Though we know that children treated inchildhood for malignancies with chemotherapy are at risk ofdeveloping second malignancies, malignant melanoma is not atpresent recognised as such a second malignancy. Long termfollow up of these children already occurs, and it isrecommended that they should have periodic skinexaminations.’Baird EA, et al. Effect of maintenance chemotherapy in childhood on numbers ofmelanocytic naevi. BMJ 305: 799-801, 3 Oct 1992 - Scotland 800155415
1
Reactions 17 Oct 1992 No. 4230114-9954/10/0423-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
